B. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc
's stock had its "buy" rating restated by investment analysts at B. Riley in a research note issued to investors on Wednesday. They presently have a $2.30 price target on the biotechnology company's stock.
from Biotech News
0 Comments